Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Cyrus Rustam Mehta, Ph.D.

Title
Institution
Department
Address
Phone
Other Positions
Title
Institution
Department

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. 261201000091C-0-0-1 (MEHTA, CYRUS R) Sep 24, 2010 - Jun 23, 2011
    NIH/NCI
    TAS::75 0849::TAS FACILITATING THE TRANSFER OF STATISTICAL METHODOLOGY INTO PRAC
    Role: Principal Investigator
  2. R43CA150519 (MEHTA, CYRUS R) Jun 11, 2010 - Nov 30, 2011
    NIH/NCI
    Statistical Software for Adaptive Oncology Clinical Trials
    Role: Principal Investigator
  3. R44CA093112 (MEHTA, CYRUS R) Jul 20, 2001 - Jan 31, 2006
    NIH/NCI
    Markov Chain Monte Carlo and Exact Logistic Regression
    Role: Principal Investigator
  4. R43CA093112 (MEHTA, CYRUS R) Jul 20, 2001 - Jan 19, 2002
    NIH/NCI
    Markov Chain Monte Carlo and Exact Logistic Regression
    Role: Principal Investigator
  5. R44CA084801 (MEHTA, CYRUS R) Feb 1, 2001 - Jan 31, 2003
    NIH/NCI
    INFORMATION BASED DESIGN AND INTERIM MONITORING SOFTWARE
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Cavender MA, White WB, Liu Y, Massaro JM, Bergenstal RM, Mehta CR, Zannad F, Heller S, Cushman WC, Cannon CP. Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. Clin Cardiol. 2018 Aug; 41(8):1022-1027. PMID: 29652078.
    Citations:    Fields:    Translation:Humans
  2. Mehta CR, Constantinidis A, Farhat M, Suthersan M, Graham E, Kanawati A. The distance of the femoral neurovascular bundle from the hip joint: an intraoperative guide to reduce iatrogenic injury. J Orthop Surg Res. 2018 Jun 04; 13(1):135. PMID: 29866137.
    Citations:    Fields:    
  3. Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab. 2018 03; 20(3):654-659. PMID: 29064626.
    Citations:    Fields:    Translation:Humans
  4. Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CSP, Lip GYH, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle HJ, Zannad F, Anker SD. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail. 2017 11; 19(11):1390-1400. PMID: 28836359.
    Citations: 11     Fields:    Translation:Humans
  5. Mehta C. Commentary on Freidlin and Korn. Clin Trials. 2017 12; 14(6):605-608. PMID: 28776412.
    Citations:    Fields:    
  6. Tamhane AC, Gou J, Jennison C, Mehta CR, Curto T. A gatekeeping procedure to test a primary and a secondary endpoint in a group sequential design with multiple interim looks. Biometrics. 2018 03; 74(1):40-48. PMID: 28589692.
    Citations:    Fields:    
  7. Ghosh P, Liu L, Senchaudhuri P, Gao P, Mehta C. Design and monitoring of multi-arm multi-stage clinical trials. Biometrics. 2017 12; 73(4):1289-1299. PMID: 28346823.
    Citations: 2     Fields:    Translation:Humans
  8. Cavender MA, White WB, Jarolim P, Bakris GL, Cushman WC, Kupfer S, Gao Q, Mehta CR, Zannad F, Cannon CP, Morrow DA. Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). Circulation. 2017 May 16; 135(20):1911-1921. PMID: 28246236.
    Citations: 1     Fields:    Translation:Humans
  9. Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, Liu Y, Gourlie NM, Cannon CP. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes Obes Metab. 2017 05; 19(5):664-671. PMID: 28058763.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  10. Mehta C, Schäfer H, Daniel H, Irle S. Biomarker-driven population enrichment for adaptive oncology trials with time to event endpoints. Stat Med. 2016 12 10; 35(28):5320. PMID: 27813199.
    Citations:    Fields:    
  11. White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen SE, Zannad F, Kupfer S. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13. PMID: 27480840.
    Citations: 5     Fields:    Translation:Humans
  12. Bhatt DL, Mehta C. Adaptive Designs for Clinical Trials. N Engl J Med. 2016 Jul 07; 375(1):65-74. PMID: 27406349.
    Citations: 32     Fields:    Translation:Humans
  13. White WB, Kupfer S, Zannad F, Mehta CR, Wilson CA, Lei L, Bakris GL, Nissen SE, Cushman WC, Heller SR, Bergenstal RM, Fleck PR, Cannon CP. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care. 2016 Jul; 39(7):1267-73. PMID: 27289121.
    Citations: 7     Fields:    Translation:Humans
  14. Mehta C, Liu L. An objective re-evaluation of adaptive sample size re-estimation: commentary on 'Twenty-five years of confirmatory adaptive designs'. Stat Med. 2016 Feb 10; 35(3):350-8. PMID: 26757953.
    Citations:    Fields:    Translation:Humans
  15. Shimada YJ, Cannon CP, Liu Y, Wilson C, Kupfer S, Menon V, Cushman WC, Mehta CR, Bakris GL, Zannad F, White WB. Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. Am Heart J. 2016 May; 175:18-27. PMID: 27179720.
    Citations: 1     Fields:    Translation:Humans
  16. Mehta CR. Comments on "Some Challenges with Statistical Inference in Adaptive Designs" by Hung, Wang, and Yang. J Biopharm Stat. 2016; 26(2):402-4. PMID: 26428953.
    Citations:    Fields:    Translation:Humans
  17. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015 Sep; 16(9):1025-1036. PMID: 26234174.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  18. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015 May 23; 385(9982):2067-76. PMID: 25765696.
    Citations: 95     Fields:    Translation:Humans
  19. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, Phillips RJ, Caceres H, Lopez Gutierrez JC, Ballona R, Friedlander SF, Powell J, Perek D, Metz B, Barbarot S, Maruani A, Szalai ZZ, Krol A, Boccara O, Foelster-Holst R, Febrer Bosch MI, Su J, Buckova H, Torrelo A, Cambazard F, Grantzow R, Wargon O, Wyrzykowski D, Roessler J, Bernabeu-Wittel J, Valencia AM, Przewratil P, Glick S, Pope E, Birchall N, Benjamin L, Mancini AJ, Vabres P, Souteyrand P, Frieden IJ, Berul CI, Mehta CR, Prey S, Boralevi F, Morgan CC, Heritier S, Delarue A, Voisard JJ. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015 Feb 19; 372(8):735-46. PMID: 25693013.
    Citations: 55     Fields:    Translation:HumansCTClinical Trials
  20. Geiger MJ, Mehta C, Turner JR, Arbet-Engels C, Hantel S, Hirshberg B, Koglin J, Mendzelevski B, Sager PT, Shapiro D, Stewart M, Todaro TG, Gaydos B. Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes. Ther Innov Regul Sci. 2015 Jan; 49(1):50-64. PMID: 30222452.
    Citations:    
  21. Mehta C, Schäfer H, Daniel H, Irle S. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints. Stat Med. 2014 Nov 20; 33(26):4515-31. PMID: 25130879.
    Citations: 4     Fields:    Translation:Humans
  22. Gewandter JS, Dworkin RH, Turk DC, McDermott MP, Baron R, Gastonguay MR, Gilron I, Katz NP, Mehta C, Raja SN, Senn S, Taylor C, Cowan P, Desjardins P, Dimitrova R, Dionne R, Farrar JT, Hewitt DJ, Iyengar S, Jay GW, Kalso E, Kerns RD, Leff R, Leong M, Petersen KL, Ravina BM, Rauschkolb C, Rice AS, Rowbotham MC, Sampaio C, Sindrup SH, Stauffer JW, Steigerwald I, Stewart J, Tobias J, Treede RD, Wallace M, White RE. Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain. 2014 Sep; 155(9):1683-95. PMID: 24865794.
    Citations: 13     Fields:    Translation:Humans
  23. Gao P, Liu L, Mehta C. Adaptive sequential testing for multiple comparisons. J Biopharm Stat. 2014; 24(5):1035-58. PMID: 24926848.
    Citations:    Fields:    Translation:Humans
  24. Selker HP, Oye KA, Eichler HG, Stockbridge NL, Mehta CR, Kaitin KI, McElwee NE, Honig PK, Erban JK, D'Agostino RB. A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials. Clin Pharmacol Ther. 2014 Feb; 95(2):147-53. PMID: 24060819.
    Citations: 5     Fields:    Translation:Humans
  25. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 03; 369(14):1327-35. PMID: 23992602.
    Citations: 417     Fields:    Translation:Humans
  26. Gao P, Liu L, Mehta C. Exact inference for adaptive group sequential designs. Stat Med. 2013 Oct 15; 32(23):3991-4005. PMID: 23686358.
    Citations: 1     Fields:    Translation:Humans
  27. Mehta CR. Adaptive clinical trial designs with pre-specified rules for modifying the sample size: a different perspective. Stat Med. 2013 Apr 15; 32(8):1276-9. PMID: 23494662.
    Citations:    Fields:    Translation:Humans
  28. Gao P, Liu L, Mehta C. Adaptive designs for noninferiority trials. Biom J. 2013 May; 55(3):310-21. PMID: 23494872.
    Citations: 1     Fields:    Translation:Humans
  29. Tamhane AC, Wu Y, Mehta CR. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation. Stat Med. 2012 Aug 30; 31(19):2041-54. PMID: 22733687.
    Citations: 2     Fields:    Translation:Humans
  30. Tamhane AC, Wu Y, Mehta CR. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints. Stat Med. 2012 Aug 30; 31(19):2027-40. PMID: 22729929.
    Citations: 4     Fields:    Translation:Humans
  31. White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011 Oct; 162(4):620-626.e1. PMID: 21982652.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  32. Mehta CR, Gao P. Population enrichment designs: case study of a large multinational trial. J Biopharm Stat. 2011 Jul; 21(4):831-45. PMID: 21516572.
    Citations: 2     Fields:    
  33. Mehta CR, Michelson G, Salganik M, Feaster J, Allen R, Cahill AL, Fox JA, Ketchum SB, Ravandi F, Erba HP, Schiller GJ, Stuart RK, Vey N, Feldman EJ. Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia. J Clin Oncol. 2011 May 20; 29(15_suppl):TPS201. PMID: 28023504.
    Citations:    
  34. Tamhane AC, Mehta CR, Liu L. Testing a primary and a secondary endpoint in a group sequential design. Biometrics. 2010 Dec; 66(4):1174-84. PMID: 20337631.
    Citations: 8     Fields:    Translation:Humans
  35. Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: a practical guide with examples. Stat Med. 2011 Dec 10; 30(28):3267-84. PMID: 22105690.
    Citations: 20     Fields:    Translation:Humans
  36. Orloff J, Douglas F, Pinheiro J, Levinson S, Branson M, Chaturvedi P, Ette E, Gallo P, Hirsch G, Mehta C, Patel N, Sabir S, Springs S, Stanski D, Evers MR, Fleming E, Singh N, Tramontin T, Golub H. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov. 2009 12; 8(12):949-57. PMID: 19816458.
    Citations: 32     Fields:    Translation:Humans
  37. Brannath W, Mehta CR, Posch M. Exact confidence bounds following adaptive group sequential tests. Biometrics. 2009 Jun; 65(2):539-46. PMID: 18759843.
    Citations: 1     Fields:    
  38. Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation. 2009 Feb 03; 119(4):597-605. PMID: 19188520.
    Citations: 15     Fields:    Translation:Humans
  39. Gao P, Ware JH, Mehta C. Sample size re-estimation for adaptive sequential design in clinical trials. J Biopharm Stat. 2008; 18(6):1184-96. PMID: 18991116.
    Citations: 5     Fields:    Translation:Humans
  40. Mehta CR, Bauer P, Posch M, Brannath W. Repeated confidence intervals for adaptive group sequential trials. Stat Med. 2007 Dec 30; 26(30):5422-33. PMID: 17918195.
    Citations: 1     Fields:    Translation:Humans
  41. Mehta CR, Patel NR. Adaptive, group sequential and decision theoretic approaches to sample size determination. Stat Med. 2006 Oct 15; 25(19):3250-69; discussion 3297-301, 3302-4, 3313-4, 3326-47. PMID: 16927402.
    Citations: 7     Fields:    Translation:Humans
  42. Mehta CR, Jemiai Y. A consultant's perspective on the regulatory hurdles to adaptive trials. Biom J. 2006 Aug; 48(4):604-8; discussion 613-22. PMID: 16972712.
    Citations: 1     Fields:    
  43. Han KE, Catalano PJ, Senchaudhuri P, Mehta C. Exact analysis of dose response for multiple correlated binary outcomes. Biometrics. 2004 Mar; 60(1):216-24. PMID: 15032792.
    Citations:    Fields:    Translation:HumansAnimals
  44. Rabbee N, Coull BA, Mehta C, Patel N, Senchaudhuri P. Power and sample size for ordered categorical data. Stat Methods Med Res. 2003 Jan; 12(1):73-84. PMID: 12617509.
    Citations: 3     Fields:    
  45. Corcoran C, Ryan L, Senchaudhuri P, Mehta C, Patel N, Molenberghs G. An exact trend test for correlated binary data. Biometrics. 2001 Sep; 57(3):941-8. PMID: 11550948.
    Citations: 5     Fields:    Translation:HumansAnimals
  46. Corcoran C, Mehta C, Patel N, Senchaudhuri P. Computational tools for exact conditional logistic regression. Stat Med. 2001 Sep 15-30; 20(17-18):2723-39. PMID: 11523079.
    Citations: 3     Fields:    Translation:HumansAnimals
  47. Corcoran C, Mehta C, Senchaudhuri P. Power comparisons for tests of trend in dose-response studies. Stat Med. 2000 Nov 30; 19(22):3037-50. PMID: 11113941.
    Citations: 2     Fields:    Translation:Animals
  48. Podgor MJ, Gastwirth JL, Mehta CR. Efficiency robust tests of independence in contingency tables with ordered classifications. Stat Med. 1996 Oct 15; 15(19):2095-105. PMID: 8896142.
    Citations: 1     Fields:    Translation:Humans
  49. Mehta CR, Patel NR. Exact logistic regression: theory and examples. Stat Med. 1995 Oct 15; 14(19):2143-60. PMID: 8552893.
    Citations: 64     Fields:    Translation:Humans
  50. Mehta CR. The exact analysis of contingency tables in medical research. Cancer Treat Res. 1995; 75:177-202. PMID: 7640163.
    Citations:    Fields:    Translation:Humans
  51. Mehta CR, Patel N, Senchaudhuri P, Tsiatis A. Exact permutational tests for group sequential clinical trials. Biometrics. 1994 Dec; 50(4):1042-53. PMID: 7786986.
    Citations:    Fields:    Translation:Humans
  52. Mehta CR. The exact analysis of contingency tables in medical research. Stat Methods Med Res. 1994; 3(2):135-56. PMID: 7952429.
    Citations: 4     Fields:    Translation:Humans
  53. Hilton JF, Mehta CR. Power and sample size calculations for exact conditional tests with ordered categorical data. Biometrics. 1993 Jun; 49(2):609-16. PMID: 8369392.
    Citations: 4     Fields:    Translation:Humans
  54. Hirji KF, Mehta CR, Patel NR. Exact inference for matched case-control studies. Biometrics. 1988 Sep; 44(3):803-14. PMID: 3203129.
    Citations: 3     Fields:    Translation:Humans
  55. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics. 1984 Sep; 40(3):819-25. PMID: 6518249.
    Citations: 36     Fields:    Translation:Humans
  56. Tsiatis AA, Rosner GL, Mehta CR. Exact confidence intervals following a group sequential test. Biometrics. 1984 Sep; 40(3):797-803. PMID: 6518248.
    Citations: 12     Fields:    Translation:Humans
  57. Ruckdeschel JC, Mehta CR, Salazar OM, Cohen M, Vogl S, Koons LS, Lerner H. Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II. Cancer Treat Rep. 1981 Nov-Dec; 65(11-12):965-72. PMID: 7028258.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu). HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Mehta's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (179)
Explore
_
Co-Authors (8)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.